Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurisco Pharmaceutical CoSHSE:605116 -1.88%78 OCF Yield % is 6.36 as of Jul. 25, 2026, which is 90% above its 10-year median of 3.34. GuruFocus rates SHSE:605116 with a GF Score™ of 78/100 and a GF Value™ of ¥28.92 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Aurisco Pharmaceutical Co ranks better than 92.27% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Aurisco Pharmaceutical Co OCF Yield % Related Terms
Aurisco Pharmaceutical Co OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:605116 vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Aurisco Pharmaceutical Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurisco Pharmaceutical Co OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurisco Pharmaceutical Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Aurisco Pharmaceutical Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurisco Pharmaceutical Co (SHSE:605116) has a OCF Yield % of 6.36 as of Jul. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Aurisco Pharmaceutical Co and its competitors. This is 90% above median its historical median of 3.34. Over the past decade, Aurisco Pharmaceutical Co's OCF Yield % has ranged from 1.08 to 6.43. According to the industry distribution chart, Aurisco Pharmaceutical Co ranks #109 out of 1410 companies in the Biotechnology industry, placing it in the top 7.7%.
Is Aurisco Pharmaceutical Co's OCF Yield % too high?
Aurisco Pharmaceutical Co's current OCF Yield % of 6.36 is 90% above median its 10-year median of 3.34. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 6.43. Based on the distribution chart, Aurisco Pharmaceutical Co ranks #109 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aurisco Pharmaceutical Co has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aurisco Pharmaceutical Co's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aurisco Pharmaceutical Co ranks #109 out of 1410 companies for OCF Yield %. This places Aurisco Pharmaceutical Co in the top 8% of its industry — outperforming the majority of peers. Historically, Aurisco Pharmaceutical Co's own OCF Yield % has ranged from 1.08 to 6.43 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Aurisco Pharmaceutical Co and its competitors. Aurisco Pharmaceutical Co's current OCF Yield % is 6.36, which is 90% above median its own 10-year median of 3.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurisco Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co (SHSE:605116) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥28.92, compared to a current price of ¥18.74 — trading 35.2% below its estimated fair value. The current OCF Yield % is 6.36, which is 90% above median its 10-year median of 3.34. Aurisco Pharmaceutical Co's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Aurisco Pharmaceutical Co (SHSE:605116), the current OCF Yield % is 6.36 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurisco Pharmaceutical Co (SHSE:605116) Overvalued in 2026?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥18.74 is trading 35.2% below its estimated GF Value™ of ¥28.92.
GuruFocus considers Aurisco Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:605116:
OCF Yield %: 6.36 (90% above median its 10-year median of 3.34)
GF Value™: ¥28.92 vs. price of ¥18.74 (35.2% below fair value)
No single metric tells the full story. See the SHSE:605116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
78GF Score
Get the complete analysis for SHSE:605116
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605116 has been successfully added to your 
